Morgan Stanley Nuvectis Pharma, Inc. Put Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding NVCT
# of Institutions
49Shares Held
3.23MCall Options Held
44.5KPut Options Held
50.1K-
Vanguard Group Inc Valley Forge, PA667KShares$4.01 Million0.0% of portfolio
-
Ronit Capital LLP563KShares$3.39 Million5.37% of portfolio
-
Iridian Asset Management LLC406KShares$2.44 Million1.02% of portfolio
-
Baldwin Brothers LLC350KShares$2.11 Million0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA285KShares$1.72 Million0.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $88.1M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...